The short version of hGH fragment fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-02-13 and is reviewed periodically as new material appears.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
== Method of transport == Hemolymph fills the whole interior (the hemocoel) of the animal's body and surrounds all cells. In the grasshopper, the closed portion of the system consists of tubular hearts and an aorta running along the dorsal side of the insect. The hearts pump hemolymph into the chambers — called sinuses — of the hemocoel where exchanges of materials take place. Coordinated movements of the body muscles gradually bring the hemolymph back to the dorsal sinus surrounding the hearts. Between contractions, tiny valves — called ostia — in the walls of the hearts open and allow hemolymph to enter. Hemolymph contains hemocyanin, a copper-based protein that turns blue when oxygenated, causing the hemolymph to turn from grey to blue-green in color. This contrasts with the iron-based hemoglobin found in the red blood cells of vertebrate blood which turns a brighter red when oxygenated. The hemolymph of lower arthropods, including most insects, contains nutrients such as proteins and sugars but is not used for oxygen transport. These animals respirate through other means, such as tracheas. Ancestral and functional hemocyanin has, however, been found in the hemolymph of some insects. Insect hemolymph generally does not carry hemoglobin, but hemoglobin may be present in the tracheal system and may play some role in respiration there. Muscular movements by the animal during locomotion can facilitate hemolymph movement, but diverting flow from one area to another is limited.
=== Standardization for Europe === DVB approved the Standard TS 101 154 V2.1.1, published (07/2014) in the DVB Blue Book A157 Specification for the use of Video and Audio Coding in Broadcasting Applications based on the MPEG-2 Transport Stream, which was published by ETSI in the following months.
Prescott DJ, Vagelos PR (1972). "Acyl carrier protein". Advances in Enzymology and Related Areas of Molecular Biology. Advances in Enzymology - and Related Areas of Molecular Biology. Vol. 36. pp. 269–311. doi:10.1002/9780470122815.ch8. ISBN 9780470122815. PMID 4561013. Vance DE, Mitsuhashi O, Bloch K (1973). "Purification and properties of the fatty acid synthetase from Mycobacterium phlei". J. Biol. Chem. 248 (7): 2303–9. doi:10.1016/S0021-9258(19)44110-0. PMID 4698221. Williamson IP, Wakil SJ (1966). "Studies on the mechanism of fatty acid synthesis. XVII. Preparation and general properties of acetyl coenzyme A and malonyl coenzyme A-acyl carrier protein transacylases". J. Biol. Chem. 241 (10): 2326–32. doi:10.1016/S0021-9258(18)96625-1. PMID 5330116. Lowe PN, Rhodes S (1988). "Purification and characterization of acyl-carrier-protein acetyltransferase from Escherichia coli". Biochem. J. 250 (3): 789–96. doi:10.1042/bj2500789. PMC 1148925. PMID 3291856. Tsay JT, Oh W, Larson TJ, Jackowski S, Rock CO (1992). "Isolation and characterization of the β-ketoacyl-acyl carrier protein synthase III gene (fabH) from Escherichia coli K-12". J. Biol. Chem. 267 (10): 6807–14. doi:10.1016/S0021-9258(19)50498-7. PMID 1551888. Rangan VS, Smith S (1997). "Alteration of the substrate specificity of the malonyl-CoA/acetyl-CoA:acyl carrier protein S-acyltransferase domain of the multifunctional fatty acid synthase by mutation of a single arginine residue". J. Biol. Chem. 272 (18): 11975–8. doi:10.1074/jbc.272.18.11975. PMID 9115261.
== Etymology and history == From the Greek words baeo (little) and kystis (bladder) 1945 P. baeocystis is first collected in Eugene, Oregon. 1958 P. baeocystis is formally described and published by Singer and Smith. 1962 Psilocin is first reported in this species. 1967-68 Baeocystin and norbaeocystin are discovered and named. 1981 Testing again reveals psilocybin, psilocin, baeocystin and norbaeocystin.
== Critical reception == After the airing of the second season, many have categorized Blue Ridge as a sleeper hit. The series began on INSP only, before streaming providers began to air the series. Pluto TV, Amazon Prime Video and Roku have all seen the show rise into their Top 10 most watched programs, more so with the second season. On Amazon, the series at times traded places with the blockbuster TV show, Reacher. The series has received steady reviews on IMDb with an overall rating of 6.6. Positive reviewers praise it as entertaining, family-friendly viewing built around a single father raising his daughter alongside his ex-wife's family, and describe him as dealing with some PTSD. On Amazon, it has received a 4.4 out of 5 rating.
Sources: en.wikipedia.org
== Uses == Proline and its derivatives are often used as asymmetric catalysts in proline organocatalysis reactions. The CBS reduction and proline catalysed aldol condensation are prominent examples. In brewing, proteins rich in proline combine with polyphenols to produce haze (turbidity). L-Proline is an osmoprotectant and therefore is used in many pharmaceutical and biotechnological applications. The growth medium used in plant tissue culture may be supplemented with proline. This can increase growth, perhaps because it helps the plant tolerate the stresses of tissue culture. For proline's role in the stress response of plants, see § Biological activity.
Clomipramine is an extremely strong SRI by all accounts. Its affinity for the SERT was reported in one study using human tissues to be 0.14 nM, which is considerably higher than that of other TCAs. For example, the TCAs with the next highest affinities for the SERT in the study were imipramine, amitriptyline, and dosulepin (dothiepin), with Ki values of 1.4 nM, 4.3 nM, and 8.3 nM, respectively. In addition, clomipramine has a terminal half-life that is around twice as long as that of amitriptyline and imipramine. In spite of these differences however, clomipramine is used clinically at the same usual dosages as other serotonergic TCAs (100–200 mg/day). Some health authorities recommend daily dosage is in the range of 30 to 75 mg in single or divided doses. Initial dosage should be 10 mg/day with gradual increments to 30–150 mg/day in divided doses or as a single dose at bedtime. Health Canada recommends maximum dose for outpatients is preferred at 200 mg/day. Sustained-release 75 mg formulation may be preferable at doses above 150 mg/day (i.e. 200 mg to 250 mg/day). It achieves typical circulating concentrations that are similar in range to those of other TCAs but with an upper limit that is around twice that of amitriptyline and imipramine. For these reasons, clomipramine is the most potent SRI among the TCAs and is far stronger as an SRI than other TCAs at typical clinical dosages. In addition, clomipramine is more potent as an SRI than any selective serotonin reuptake inhibitors (SSRIs); it is more potent than paroxetine, which is the strongest SSRI.
=== Approval === It is approved to treat complicated skin and soft tissue infections (cSSTI), complicated intra-abdominal infections (cIAI), and community-acquired bacterial pneumonia (CAP) in individuals 18 years and older. In the United Kingdom it is approved in adults and in children from the age of eight years for the treatment of complicated skin and soft tissue infections (excluding diabetic foot infections) and complicated intra-abdominal infections in situations where other alternative antibiotics are not suitable.
=== Grades of sulfuric acid === Although nearly 100% sulfuric acid solutions can be made, the subsequent loss of SO3 at the boiling point brings the concentration to 98.3% acid. The 98.3% grade, which is more stable in storage, is the usual form of what is described as "concentrated sulfuric acid". Other concentrations are used for different purposes. Some common concentrations are:
A total of 100 cities across six continents were part of the 100 Resilient Cities program funded by the Rockefeller Foundation. In January 2016, the United States Department of Housing and Urban Development announced winners of its National Disaster Resilience Competition (NDRC), awarding three 100RC member cities – New York City; Norfolk, VA; and New Orleans, LA – with more than $437 million in disaster resilience funding. The grant was the largest ever received by the city of Norfolk. In April 2019, it was announced that the foundation would no longer be funding the 100 Resilient Cities program as a whole. Some elements of the initiative's work, most prominently the funding of several cities' Chief Resilience Officer roles, continues to be managed and funded by the Rockefeller Foundation, while other aspects of the program continue in the form of two independent organizations, Resilient Cities Catalyst (RCC) and the Global Resilient Cities Network (GRCN), founded by former 100RC leadership and staff.
Sources: en.wikipedia.org
=== 1960s === 1960: Rosalyn Yalow received the Nobel Prize in Physiology or Medicine "for the development of radioimmunoassays of peptide hormones" along with Roger Guillemin and Andrew V. Schally who received it "for their discoveries concerning the peptide hormone production of the brain". 1962: Katherine Johnson performed the calculations for the NASA orbital mission, launching John Glenn as the first person into orbit and returning them safely. 1963: Maria Goeppert Mayer became the first American woman to receive a Nobel Prize in Physics; she shared the prize with J. Hans D. Jensen "for their discoveries concerning nuclear shell structure” and Eugene Paul Wigner "for his contributions to the theory of the atomic nucleus and the elementary particles, particularly through the discovery and application of fundamental symmetry principles". She was born in Poland, but became a U.S. citizen in 1933. 1965: Sister Mary Kenneth Keller became the first American woman to earn a Ph.D. in Computer Science. Her thesis was titled "Inductive Inference on Computer Generated Patterns."
Periplaneta lateralis (also Shelfordella lateralis, Blatta lateralis), commonly known as the Turkestan cockroach, red runner cockroach, or rusty red cockroach, is a primarily outdoor-dwelling cockroach native to an area stretching from northern Africa to Central Asia.
== Further reading == Fischer, H.; Esbjornsson, M.; Sabina, R. L.; Stromberg, A.; Peyrard-Janvid, M.; Norman, B. (2007). "AMP deaminase deficiency is associated with lower sprint cycling performance in healthy subjects". Journal of Applied Physiology. 103 (1): 315–22. doi:10.1152/japplphysiol.00185.2007. PMID 17463303. Skalova, K; Luptak, I; Turcani, M; Hulin, I (2002). "Adenosine and cardioprotection: what can we learn from nature's genetic polymorphism?" (PDF). Bratislavske Lekarske Listy. 103 (6): 187–93. PMID 12448564. Archived from the original (PDF) on 2012-03-23. Retrieved 2011-08-12.
The Hassuna culture is a Neolithic archaeological culture in northern Mesopotamia dating to the early sixth millennium BC. It is named after the type site of Tell Hassuna in Iraq. Other sites where Hassuna material has been found include Tell Shemshara.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.